Prostate Cancer | Tumor

Sharing a Cancer Diagnosis with Family, in Verse

June 21st 2022

Looking back, perhaps a poem could have helped me tell my family about my cancer diagnosis.

Educated Patient® Prostate Cancer Summit Looking Ahead Panel: May 21, 2022

June 17th 2022

Watch Dr. Jeremie Calais, Dr. Tian Zhang, Dr. Landon C. Brown and Jim Rosenfield answer questions about novel agents and strategies during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Approaches to Hormone Therapy Presentation: May 21, 2022

June 16th 2022

Watch Dr. Landon C. Brown, from Atrium Health Levine Cancer Institute, discuss approaches to hormone therapy, during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Novel Agents Presentation: May 21, 2022

June 15th 2022

Watch Dr. Tian Zhang, from UT Southwestern Medical Center, discuss novel agents, during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Novel Imaging Strategies Presentation: May 21, 2022

June 14th 2022

Watch Dr. Jeremie Calais, from UCLA, discuss novel imaging strategies, during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Genetics & Genomics Panel: May 21, 2022

June 13th 2022

Watch Dr. Veda N. Giri, Dr. Umang Swami and Sue Friedman answer questions about genetics and genomics during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Genomics Presentation: May 21, 2022

June 12th 2022

Watch Dr. Umang Swami, from Huntsman Cancer Institute, discuss genomic changes and PARP inhibitors, during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Genetic Testing Presentation: May 21, 2022

June 11th 2022

Watch Dr. Veda N. Giri, from Sidney Kimmel Cancer Center at Thomas Jefferson University, discuss genetic testing and who should get it, during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Treatment in Localized Disease Panel: May 21, 2022

June 10th 2022

Watch Dr. Ganesh Raj, Dr. Andrew Z. Wang, and Bruce Williams, discuss treatment for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Approaches to Radiation Presentation: May 21, 2022

June 9th 2022

Watch Dr. Andrew Z. Wang, from UT Southwestern Medical Center, discuss approaches to radiation for local disease, during the CURE Educated Patient Prostate Cancer Summit.

Educated Patient® Prostate Cancer Summit Overview of Surgery Presentation: May 21, 2022

June 8th 2022

Watch Dr. Ganesh V. Raj, from UT Southwestern Medical Center, discuss surgery for localized disease, during the CURE Educated Patient Prostate Cancer Summit.

Actress Alicia Witt Discusses Cancer Treatment After Losing Her Parents, Chef Gordon Ramsay Surprises a Teen With Cancer and More

June 3rd 2022

From chef Gordon Ramsay sharing a meal with a 13-year-old fan with Ewing sarcoma, to a dermatologist on a playground spotting a mother’s skin cancer, here’s a look at what’s happening in the cancer space this week.

Overview of Metastatic Castration Resistant Prostate Cancer (mCRPC)

June 1st 2022

An overview of metastatic castration-resistant prostate cancer (mCRPC) and the role of PSMA in mCRPC.

Targeted therapy improves outcomes for some metastatic prostate cancer

May 31st 2022

Certain Latino and Hispanic Men More Likely to Be Diagnosed With High-Risk Prostate Cancer

May 19th 2022

Despite Latino and Hispanic men being more likely to present with higher-risk prostate cancer, they are less likely to receive treatment for their disease compared to other ethnicities.

Cancer Creates Empathy, But Hope Must Prevail

May 16th 2022

After experiencing cancer, I feel a profound sense of empathy for others in tough situations, from the war in Ukraine to COVID-19.

Zytiga-Containing Regimen Boosts Survival in Certain Patients With Prostate Cancer

May 6th 2022

Treatment with androgen deprivation therapy in combination with Zytiga, docetaxel and prednisone improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

FDA Expedites Review of Nubeqa Combination for Metastatic, Hormone-Sensitive Prostate Cancer

May 3rd 2022

Results from a phase 3 trial showed that the combination of Nubeqa, docetaxel and androgen-deprivation therapy significantly decreased the risk of death for men with a certain type of prostate cancer.

Older Patients With Prostate Cancer at a Higher Risk for Heart Complications After Androgen-Deprivation Therapy

May 3rd 2022

While a higher risk of heart issues was found in older men years after androgen-deprivation therapy, it is unknown if the risk comes from the treatment or other age-related comorbidities.

Dear John Wayne: Let’s Cut ‘the Big C’ Down to Size, Because Cancer Is a Coward

May 2nd 2022

John Wayne coined the term, “the Big C,” for cancer, but I think it’s time that the capital letter C stands for something better.

10-Year-Old Child With Cancer Sworn in as Honorary Member of NYPD, Experts Suggest a New Name for Certain Prostate Cancers and More

April 22nd 2022

From Philadelphia Flyers’ employees suing the organization after developing a rare blood cancer to experts proposing a new name for low-risk prostate cancer and an actor on Disney+’s “The Mandolorian” dying of cancer, here’s what is happening in the cancer space this week.

Trial to Evaluate Safety, Efficacy of Novel Drug for Various Solid Tumors Treats First Patient

April 15th 2022

The primary focus of the trial is to evaluate the incidence of treatment-emergent and serious side effects in patients receiving either the novel drug alone or in combination with Keytruda.

Cancer Survivor to Run Boston Marathon Alongside His Organ Donor, HIV Drug Shows Promise in Treating Metastatic Colon Cancer and More

April 8th 2022

From liver cancer survivor planning to run the upcoming Boston Marathon with his organ donor to a common HIV drug showing promise in treating colorectal cancer, here’s what’s happening in the cancer space this week.

FDA’s Approval of Pluvicto Gives Some Patients With Prostate Cancer a ‘Truly Targeted Therapy’ With Modest Side Effects

March 28th 2022

A recently FDA-approved drug offers patients with metastatic castration-resistant prostate cancer a newer treatment that improves survival, but is not curative of the disease, which means that more research is needed, according to an expert.

FDA Approves First PSMA-Targeted Therapy for Metastatic Castration-Resistant Prostate Cancer

March 23rd 2022

Patients with PSMA-positive metastatic castration-resistant prostate cancer can now be treated with Pluvicto, which may provide hope to an unmet need in this patient population.

Actor William Hurt Dies of Prostate Cancer, Several Cancer Centers Establish Helpline to Connect Ukrainian Patients to Cancer Care and More

March 18th 2022

From two celebrity deaths due to cancer to leading American cancer organizations coming together to help patients with cancer fleeing Ukraine, here’s what’s happening in the cancer space this week.

Merck Stops Trial After Analysis Reveals Keytruda Plus Lynparza Was Ineffective in Prostate Cancer Treatment

March 16th 2022

In a news release, Merck advised patients enrolled on the trial to consult with their health care provider regarding their treatment.

Male Cancer Caregivers Navigate A Gauntlet of Challenges, Often Under The Cover of Darkness

March 15th 2022

Regardless of a man’s age, providing care to a partner or family member with cancer has been shown to take a drastic toll on their health. To make matters worse, research shows many men struggle in silence.

PSMA-Targeted Treatment Improves Bone-Related Pain in Metastatic, Castration-Resistant Prostate Cancer

March 7th 2022

Patients treated with Lutetium-177 PSMA-617 tended to experience improvements in quality of life related to the aches and pains that can come from bone metastases.

Even in the Prescence of Health Complications and Other Medications, Nubeqa Maintains Safety, Efficacy in Prostate Cancer Treatment

February 21st 2022

Patients with nonmetastatic castration-resistant prostate cancer who were taking other medications or had health complications still derived a survival benefit from treatment with Nubeqa, research showed.